JP2018536002A5 - - Google Patents

Download PDF

Info

Publication number
JP2018536002A5
JP2018536002A5 JP2018528691A JP2018528691A JP2018536002A5 JP 2018536002 A5 JP2018536002 A5 JP 2018536002A5 JP 2018528691 A JP2018528691 A JP 2018528691A JP 2018528691 A JP2018528691 A JP 2018528691A JP 2018536002 A5 JP2018536002 A5 JP 2018536002A5
Authority
JP
Japan
Prior art keywords
vaccine composition
domain
mic
fusion protein
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018528691A
Other languages
English (en)
Japanese (ja)
Other versions
JP7099956B2 (ja
JP2018536002A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/064969 external-priority patent/WO2017096374A1/en
Publication of JP2018536002A publication Critical patent/JP2018536002A/ja
Publication of JP2018536002A5 publication Critical patent/JP2018536002A5/ja
Priority to JP2022105405A priority Critical patent/JP7564842B2/ja
Application granted granted Critical
Publication of JP7099956B2 publication Critical patent/JP7099956B2/ja
Priority to JP2024167997A priority patent/JP2024177207A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018528691A 2015-12-04 2016-12-05 がんの治療のためのｍｉｃａ／ｂアルファ３ドメインによるワクチン接種 Active JP7099956B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022105405A JP7564842B2 (ja) 2015-12-04 2022-06-30 がんの治療のためのｍｉｃａ／ｂアルファ３ドメインによるワクチン接種
JP2024167997A JP2024177207A (ja) 2015-12-04 2024-09-27 がんの治療のためのｍｉｃａ／ｂアルファ３ドメインによるワクチン接種

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562263377P 2015-12-04 2015-12-04
US62/263,377 2015-12-04
US201662422454P 2016-11-15 2016-11-15
US62/422,454 2016-11-15
PCT/US2016/064969 WO2017096374A1 (en) 2015-12-04 2016-12-05 Vaccination with mica/b alpha 3 domain for the treatment of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022105405A Division JP7564842B2 (ja) 2015-12-04 2022-06-30 がんの治療のためのｍｉｃａ／ｂアルファ３ドメインによるワクチン接種

Publications (3)

Publication Number Publication Date
JP2018536002A JP2018536002A (ja) 2018-12-06
JP2018536002A5 true JP2018536002A5 (enExample) 2020-01-16
JP7099956B2 JP7099956B2 (ja) 2022-07-12

Family

ID=57590885

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018528691A Active JP7099956B2 (ja) 2015-12-04 2016-12-05 がんの治療のためのｍｉｃａ／ｂアルファ３ドメインによるワクチン接種
JP2022105405A Active JP7564842B2 (ja) 2015-12-04 2022-06-30 がんの治療のためのｍｉｃａ／ｂアルファ３ドメインによるワクチン接種
JP2024167997A Pending JP2024177207A (ja) 2015-12-04 2024-09-27 がんの治療のためのｍｉｃａ／ｂアルファ３ドメインによるワクチン接種

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022105405A Active JP7564842B2 (ja) 2015-12-04 2022-06-30 がんの治療のためのｍｉｃａ／ｂアルファ３ドメインによるワクチン接種
JP2024167997A Pending JP2024177207A (ja) 2015-12-04 2024-09-27 がんの治療のためのｍｉｃａ／ｂアルファ３ドメインによるワクチン接種

Country Status (24)

Country Link
US (3) US10993971B2 (enExample)
EP (1) EP3383426A1 (enExample)
JP (3) JP7099956B2 (enExample)
KR (1) KR20180088458A (enExample)
CN (1) CN108770343A (enExample)
AU (3) AU2016362597C1 (enExample)
BR (1) BR112018010705A8 (enExample)
CA (1) CA3005910A1 (enExample)
CL (3) CL2018001470A1 (enExample)
CO (1) CO2018006642A2 (enExample)
CR (2) CR20230116A (enExample)
CU (2) CU24609B1 (enExample)
EA (1) EA201891287A1 (enExample)
IL (1) IL259490A (enExample)
MX (2) MX2018006785A (enExample)
MY (1) MY199248A (enExample)
NZ (1) NZ742663A (enExample)
PE (2) PE20181158A1 (enExample)
PH (1) PH12018501170A1 (enExample)
RU (2) RU2021109510A (enExample)
SG (1) SG11201804597TA (enExample)
TN (1) TN2018000187A1 (enExample)
WO (1) WO2017096374A1 (enExample)
ZA (1) ZA202204223B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7614841B2 (ja) 2018-04-03 2025-01-16 サノフイ 抗原性呼吸器合胞体ウイルスポリペプチド
EP3773698A1 (en) 2018-04-03 2021-02-17 Sanofi Ferritin proteins
CN112512566A (zh) 2018-04-03 2021-03-16 赛诺菲 抗原性爱泼斯坦-巴尔病毒多肽
KR20210018205A (ko) 2018-04-03 2021-02-17 사노피 항원성 OspA 폴리펩타이드
WO2021174132A2 (en) * 2020-02-26 2021-09-02 The Wistar Institute Of Anatomy & Biology Compositions comprising self-assembling vaccines and methods of using the same
KR20230152783A (ko) 2020-07-07 2023-11-03 칸큐어 엘엘씨 Mic 항체 및 결합제 및 이의 사용 방법
CN116396398B (zh) * 2023-01-16 2024-07-16 四川大学 一种实现铁蛋白纳米颗粒可控自组装的方法以及基于该方法搭建的纳米颗粒抗原展示平台
WO2024222886A1 (zh) * 2023-04-28 2024-10-31 北京先声祥瑞生物制品股份有限公司 一种针对MICA/B靶点的mRNA肿瘤疫苗

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4709017A (en) 1985-06-07 1987-11-24 President And Fellows Of Harvard College Modified toxic vaccines
US4950740A (en) 1987-03-17 1990-08-21 Cetus Corporation Recombinant diphtheria vaccines
DE3841091A1 (de) 1988-12-07 1990-06-13 Behringwerke Ag Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
DE68907045T2 (de) 1989-01-17 1993-12-02 Eniricerche Spa Synthetische Peptide und deren Verwendung als allgemeine Träger für die Herstellung von immunogenischen Konjugaten, die für die Entwicklung von synthetischen Impfstoffen geeignet sind.
JPH04506662A (ja) 1989-07-14 1992-11-19 アメリカン・サイアナミド・カンパニー 接合体ワクチンのためのサイトカイニンおよびホルモンのキヤリヤー
US5073627A (en) 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
DE69113564T2 (de) 1990-08-13 1996-05-30 American Cyanamid Co Faser-Hemagglutinin von Bordetella pertussis als Träger für konjugierten Impfstoff.
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
ATE178907T1 (de) 1992-05-06 1999-04-15 Harvard College Rezeptorbindende region des diphtherietoxius
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
US5917017A (en) 1994-06-08 1999-06-29 President And Fellows Of Harvard College Diphtheria toxin vaccines bearing a mutated R domain
US6455673B1 (en) 1994-06-08 2002-09-24 President And Fellows Of Harvard College Multi-mutant diphtheria toxin vaccines
CA2271720A1 (en) 1996-10-31 1998-05-07 Human Genome Sciences, Inc. Streptococcus pneumoniae polynucleotides and sequences
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
JP2002539273A (ja) 1999-03-19 2002-11-19 スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム ワクチン
CA2365914A1 (en) 1999-04-09 2000-10-19 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
US20030035806A1 (en) 2001-05-11 2003-02-20 D'ambra Anello J. Novel meningitis conjugate vaccine
CA2462455C (en) 2001-10-01 2012-07-17 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Development of a preventive vaccine for filovirus infection in primates
US6706305B2 (en) 2001-10-31 2004-03-16 Conagra Foods Inc. Low glycemic index bread
US7097841B2 (en) * 2002-05-10 2006-08-29 New Century Pharmaceuticals, Inc. Ferritin fusion proteins for use in vaccines and other applications
EP1809738B1 (en) 2004-11-02 2014-03-05 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services Compositions and methods for treating hyperproliferative disorders
GB0428394D0 (en) 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
US8110196B2 (en) 2005-04-29 2012-02-07 Polytopas LLC Methods and compositions for polytopic vaccination
US20070104689A1 (en) * 2005-09-27 2007-05-10 Merck Patent Gmbh Compositions and methods for treating tumors presenting survivin antigens
CA2665090A1 (en) 2006-09-22 2008-03-27 Dana-Farber Cancer Institute, Inc. Methods for treating mica-related disorders
US8182809B1 (en) * 2008-09-08 2012-05-22 University Of Washington Methods for treating cancer by inhibiting MIC shedding
US20120269721A1 (en) 2009-10-12 2012-10-25 The Regents Of The University Of California Targeted nanoclusters and methods of their use
US8889044B2 (en) 2009-12-18 2014-11-18 Kao Corporation Method for producing mesoporous silica particles
JP5603063B2 (ja) 2009-12-21 2014-10-08 花王株式会社 複合シリカ粒子の製造方法
RU2489169C2 (ru) * 2010-10-12 2013-08-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Новосибирский национальный исследовательский государственный университет" (Новосибирский государственный университет, НГУ) Способ лечения онкологических заболеваний
KR20140069222A (ko) * 2011-09-23 2014-06-09 유니버시티 오브 오슬로 교차 제시 수지상 세포를 표적으로 하는 백시바디
PT2760471T (pt) 2011-09-30 2017-03-22 Dana Farber Cancer Inst Inc Péptidos terapêuticos
WO2013117647A1 (en) * 2012-02-07 2013-08-15 Innate Pharma Mica binding agents
PT2838515T (pt) 2012-04-16 2020-02-25 Harvard College Composições de sílica mesoporosa para modular respostas imunológicas
US10851148B2 (en) 2013-03-15 2020-12-01 Novelogics Biotechnology, Inc. Antibodies to MICA and MICB proteins
NZ629816A (en) 2013-03-15 2017-07-28 Dana Farber Cancer Inst Inc Therapeutic peptides
CN113491766A (zh) * 2014-03-14 2021-10-12 达纳－法伯癌症研究所公司 恢复对抗癌症的nkg2d通路功能的疫苗组合物和方法

Similar Documents

Publication Publication Date Title
JP2023513720A5 (enExample)
ES2848064T3 (es) Vacuna terapéutica potenciadora de inmunidad para VPH y enfermedades relacionadas
RU2018123307A (ru) Вакцинация с использованием альфа3 домена mica/b для лечения рака
JP2020528911A5 (enExample)
Fifis et al. Short peptide sequences containing MHC class I and/or class II epitopes linked to nano-beads induce strong immunity and inhibition of growth of antigen-specific tumour challenge in mice
PE20240645A1 (es) Peptido inmunogenico derivado de moleculas de antigenos leucocitarios humanos (hla) como biomarcador en la inmunoterapia de diversos tumores
JP2021531345A5 (enExample)
PE20181490A1 (es) Tratamientos contra el cancer de utero
JP2006020648A5 (enExample)
JP2016128513A5 (enExample)
EP3545965A3 (en) Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancers
JP2016516723A5 (enExample)
JP2012501959A5 (enExample)
JP2016539946A5 (enExample)
JP2020506690A5 (enExample)
JP2008530245A5 (enExample)
WO2011113819A3 (en) Diagnosis and treatment of cancer based on avl9
JP2018509163A5 (enExample)
Xiang et al. Promising particle-based vaccines in cancer therapy
JP2019531293A5 (enExample)
JP2012517799A5 (enExample)
JP2022130623A5 (enExample)
JP2014502961A5 (enExample)
JP2012021028A5 (enExample)
JP2015533376A5 (enExample)